Indication
Membranoproliferative Glomerulonephritis
7 clinical trials
6 products
Product
PegcetacoplanClinical trial
US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With PegcetacoplanStatus:
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGNStatus: Active (not recruiting), Estimated PCD: 2023-02-27
Clinical trial
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisStatus: Active (not recruiting), Estimated PCD: 2027-07-01
Product
DanicopanClinical trial
An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471Status: Terminated, Estimated PCD: 2021-03-29
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN)Status: Recruiting, Estimated PCD: 2026-10-23
Product
PlaceboProduct
iptacopanClinical trial
Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 GlomerulopathyStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AliskirenProduct
Enalapril